Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Early Trial of Anti-PD-L1 Agent Shows Promise in TNBC
April 21st 2015The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer (TNBC), according to findings from an ongoing phase I study presented at the 2015 AACR Annual Meeting.
Telephone Intervention Helps Breast Cancer Survivors Set-and Meet-Lifestyle Goals
April 15th 2015A new telephone-based intervention for breast cancer survivors is showing promise, and it involves them becoming more actively engaged in goal setting and problem solving with an eye toward accelerating their recovery by engaging in health-promoting activities such as exercise, stress management, and healthy eating.
An Unmet Need-Discussing Genetic Risk May Benefit All Patients With Breast Cancer
April 9th 2015Many women who are diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer. However, a large amount of those concerns are not being addressed, according to a new study.
Not "One-Size Fits All"-Jolie Pitt's Story Spotlights Hereditary Cancer Risks
April 8th 2015Angelina Jolie Pitt recently added another chapter to her BRCA mutation story, making public her choice to undergo a preventive salpingo-oophorectomy, removal of her ovaries and fallopian tubes to reduce her risk of cancer.
Dr. Hudis on the Challenges of Understanding Obesity and Cancer
March 31st 2015Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the challenges of understanding the link between obesity and cancer.
Practicing Stress Management Improves Long-Term Mood, Quality of Life in Women with Breast Cancer
March 23rd 2015Results of a follow up study have shown that when women were taught stress management techniques early in their breast cancer treatment, their mood and quality of life continued to improve up to 15 years later.
Higher Risk of Thyroid Cancer Among Those With Breast Cancer History
March 10th 2015According to a recent retrospective cohort analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than do the general population, particularly if they receive adjuvant radiation therapy.
Dixon Questions Value of Chemoprevention With Tamoxifen
March 2nd 2015The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who discussed his position at the 32nd Annual Miami Breast Cancer Conference on Sunday.
Ovarian Suppression Emerges as Practice-Changing Option for Premenopausal Breast Cancer Patients
February 20th 2015Women with HR-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent- tamoxifen compared with standard tamoxifen alone, according to results from the phase III SOFT trial.
Palbociclib Approval Will Improve Quality of Life for Late-Stage Breast Cancer Patients
February 6th 2015The big difference in progression-free survival seen in pivotal trial data propelled palbociclib to its accelerated FDA approval for the treatment of metastatic breast cancer, bringing with it the potential for the drug to quickly become adapted as the new standard of care, Brian Wojciechowski, MD, said.
Dr. Cuzick Discusses Women at High Risk of Developing Breast Cancer
February 3rd 2015Jack Cuzick, PhD, a professor of epidemiology at Wolfson Institute of Preventive Medicine, discusses how to determine if a woman is at high risk of developing breast cancer and which of these women should consider taking tamoxifen as a preventative measure.
Radiation Therapy in Early-Stage Breast Cancer: When Less Is More
January 30th 2015Women diagnosed with early-stage breast disease have a variety of decisions to make regarding their treatment options. For example, some women may be eligible for breast-conserving surgery, which typically includes a lumpectomy followed by radiation.